about
Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placentaStructure and function of ATA3, a new subtype of amino acid transport system A, primarily expressed in the liver and skeletal musclebeta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transportercDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system AEvidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system AInvolvement of transporter recruitment as well as gene expression in the substrate-induced adaptive regulation of amino acid transport system A.Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantationRegulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat skeletal muscle cells by insulin, osmotic shock and amino acid deprivation.Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters.Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes.Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract.Ionic strength has a greater effect than does transmembrane electric potential difference on permeation of tryptamine and indoleacetic acid across Caco-2 cells.Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection.Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney.An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs.Major role of organic anion transporters in the uptake of phenolsulfonphthalein in the kidney.A new system for the prediction of drug absorption using a pH-controlled Caco-2 model: evaluation of pH-dependent soluble drug absorption and pH-related changes in absorption.Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts.Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate.Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein.The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations.Structure-affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites.Phenolsulfonphthalein transport by potential-sensitive urate transport system.Functional analysis of phenolsulfonphthalein transport system in Long-Evans Cinnamon rats.Protective effect of lutein after ischemia-reperfusion in the small intestine.Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein.Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibe.Effect of membrane surface potential on the uptake and the inhibition of cationic compounds in rat intestinal brush-border membrane vesicles and liposomes.Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.A general approach for the prediction of the intestinal absorption of drugs: regression analysis using the physicochemical properties and drug-membrane electrostatic interaction.Mechanism of the inhibitory effect of imipramine on the Na+-dependent transport of L-glutamic acid in rat intestinal brush-border membrane.Transport mechanisms of nucleosides and the derivative, 6-mercaptopurine riboside across rate intestinal brush-border membranes.Estimation of the duration after methamphetamine injection using a pharmacokinetic model in suspects who caused fatal traffic accidents.Membrane-potential-dependent uptake of tryptamine by rat intestinal brush-border membrane vesiclesCarrier-mediated transport system for choline and its related quaternary ammonium compounds on rat intestinal brush-border membraneThe transport mechanisms of organic cations and their zwitterionic derivatives across rat intestinal brush-border membrane. II. Comparison of the membrane potential effect on the uptake by membrane vesicles
P50
Q22254594-EB8F9346-25D6-48F3-9C05-82E3B7CA5568Q28577556-68E95485-E2AA-40E1-BB83-A2FC458CE2E7Q28584010-963F4BA6-4C70-4EBD-90F9-87594FD2D344Q28586773-9148D2C6-C23D-4197-BC96-DB850AFB726BQ28609233-517DAD15-7DDB-4BAA-A7E0-74BB9852C518Q28609235-EC478958-1614-4514-850D-62AD51FDF1F2Q30665686-64C53F0B-CBBB-44FD-96D9-705AC23CB9A0Q34708786-075F9B65-04CA-4468-A378-43FCC980B03FQ37157699-3D02EA3D-2D1F-4B81-B912-E27375DE2FFBQ40004165-F73D18E8-CE03-424C-B003-DB8D18BAC368Q40202073-C9EC665E-C6B8-450D-8F3C-D8611D0F760DQ42284221-D93B6143-EEDC-488D-A4AB-F5388EC8562DQ43185498-8E1A08F2-F1FF-49D5-9305-A40A1B90896BQ43633562-DB70C201-464F-4835-A59F-603F5C4065E2Q44052414-5BF28D22-30F2-4C67-B47D-5EB657EDC481Q44194910-566BCBC7-C310-40EA-91EC-8D273B162080Q44250245-722F22E8-9777-4C8B-9CC0-E7E4559DC16FQ44266764-9794EF0D-AD2E-4DA8-AD2E-1B32B694C7C1Q44572378-D42F1795-D635-4C5D-903F-8CEE10B066ABQ44572490-9AFDA090-FF25-4E85-A6C9-E43494D9289FQ44675738-8512571D-74FA-4087-81A8-ECA28CF173E2Q44712173-BB384407-58CC-48E3-A286-EBE6A5FBC362Q45025022-94811F7B-C3EE-4888-A1A8-DF7ECF92BB70Q46461477-E8127668-EB99-4B94-B2F6-9BD4E2AF89DEQ46551227-69B607D9-3E54-436F-9E8A-5BA612C65776Q46614503-DC9AE183-923F-4DA2-B899-7E0237E23352Q46637646-7BC1C194-B4E4-447A-BE03-3C69E1C38117Q46919610-BC7CCE85-2D63-41EA-9EA7-3A2081D86E1FQ50436469-A002963B-3E39-4439-BC90-724418689F57Q50526715-308D5ADD-913F-4DF2-BAA8-7D15AD6755B9Q50986997-B817FCF4-CA90-4B62-827D-9545E2862F55Q51608354-41A34C47-47D2-4ECF-9D52-07A60436DAC7Q51921353-F2CFDAB8-A83D-4A3A-AFA2-F096D5DAD42AQ52238684-DBD1F0AA-E11A-40A0-AD35-5F3623E17E1BQ52243595-ED612CA8-4995-4C37-A740-C2ADC02FF215Q52312819-F4CFCC27-12CC-49FD-BE0E-940BF0C85064Q54314690-16F3A37B-1D32-4388-A78C-AB8ADF9DC4B4Q67505530-2BED81FC-7EA7-4514-B328-CE3C0721BFBCQ67571076-2CB41646-34DB-41DA-BC3D-E09B5BC0279DQ70480866-03A9515B-1C46-4255-8E16-56C2C94D6E30
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mitsuru Sugawara
@ast
Mitsuru Sugawara
@en
Mitsuru Sugawara
@es
Mitsuru Sugawara
@nl
Mitsuru Sugawara
@sl
Мицуру Сугавара
@ru
type
label
Mitsuru Sugawara
@ast
Mitsuru Sugawara
@en
Mitsuru Sugawara
@es
Mitsuru Sugawara
@nl
Mitsuru Sugawara
@sl
Мицуру Сугавара
@ru
prefLabel
Mitsuru Sugawara
@ast
Mitsuru Sugawara
@en
Mitsuru Sugawara
@es
Mitsuru Sugawara
@nl
Mitsuru Sugawara
@sl
Мицуру Сугавара
@ru
P1053
A-5274-2012
P106
P31
P3829
P496
0000-0001-5350-2950